

FOR IMMEDIATE RELEASE

April 27, 2015

Eisai Co., Ltd.
Nihon Medi-Physics Co., Ltd.

**EISAI AND NIHON MEDI-PHYSICS ENTER COLLABORATION AGREEMENT
TO CONTRIBUTE TO DIAGNOSIS AND TREATMENT OF
DEMENTIA WITH LEWY BODIES**

Eisai Co., Ltd. (Headquarters: Tokyo, Representative Corporate Officer and CEO: Haruo Naito, "Eisai") and Nihon Medi-Physics (Headquarters: Tokyo, Representative Corporate Officer and CEO: Tetsuya Kato, "Nihon Medi-Physics") have entered into a collaboration agreement to contribute to the diagnosis and treatment of dementia with Lewy bodies (DLB), alongside Alzheimer's disease and vascular dementia. According to a number of reports, DLB affects between 4.3%*

1

(based on epidemiology) and 41.4%*² (based on autopsies) of elderly patients with dementia in Japan, with the number of patients increasing due to the aging of the population. It is pointed out that DLB is difficult to be diagnosed because the disease presents characteristic symptoms such as cognitive fluctuations, visual hallucinations and parkinsonism in addition to progressive cognitive impairment.

Nihon Medi-Physics markets the brain disorder diagnostic agent DaTSCAN[®] Injectable (ioflupane [¹²³I], "DaTSCAN"), which is the only product indicated for the use of dopamine transporter scintigraphy in diagnosing DLB in Japan. DaTSCAN is a radiopharmaceutical for use in Single Photon Emission Computed Tomography (SPECT) imaging. Low dopamine transporter uptake in basal ganglia, one of the suggestive features included in the criteria for clinical diagnosis of DLB (determined at the 3rd international workshop on DLB), can be verified by an examination using DaTSCAN and contributes to improving the accuracy of DLB diagnosis and influencing decisions on treatment strategy.

On the other hand, Eisai markets Aricept[®] (donepezil hydrochloride), the world's only treatment approved for the suppression of progression of dementia symptoms in DLB in Japan. Eisai has a wealth of experience and knowledge gained from more than 30 years of drug discovery in the field of dementia and information provision activities for Aricept.

Based on this agreement, both companies will share with each other information on the dementia including DLB, and work to generate new evidence as well as hold study meetings in order to improve the diagnosis and treatment of DLB.

Through this collaboration, Eisai and Nihon Medi-Physics will contribute to the diagnosis and treatment of DLB in order to further contribute to addressing the diverse needs of, and providing increased benefits to patients with DLB, and their families.

Media Inquiries	
Public Relations Department Eisai Co., Ltd. TEL: +81-(0)3-3817-5120	General Affairs Department Nihon Medi-Physics Co., Ltd. TEL: +81-(0)6-4300-5541

